

<!-- === R3.htm === -->



| CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Millions | 12 Months Ended |   |   |
| --- | --- | --- | --- |
|   | Sep. 28, 2024 | Sep. 30, 2023 | Sep. 24, 2022 |
| Net sales | 391035 | 383285 | 394328 |
| Cost of sales | 210352 | 214137 | 223546 |
| Gross margin | 180683 | 169148 | 170782 |
| Operating expenses: |   |   |   |
| Research and development | 31370 | 29915 | 26251 |
| Selling, general and administrative | 26097 | 24932 | 25094 |
| Total operating expenses | 57467 | 54847 | 51345 |
| Operating income | 123216 | 114301 | 119437 |
| Other income/(expense), net | 269 | -565 | -334 |
| Income before provision for income taxes | 123485 | 113736 | 119103 |
| Provision for income taxes | 29749 | 16741 | 19300 |
| Net income | 93736 | 96995 | 99803 |
| Earnings per share: |   |   |   |
| Basic (in dollars per share) | 6.11 | 6.16 | 6.15 |
| Diluted (in dollars per share) | 6.08 | 6.13 | 6.11 |
| Shares used in computing earnings per share: |   |   |   |
| Basic (in shares) | 15343783 | 15744231 | 16215963 |
| Diluted (in shares) | 15408095 | 15812547 | 16325819 |
| Products |   |   |   |
| Net sales | 294866 | 298085 | 316199 |
| Cost of sales | 185233 | 189282 | 201471 |
| Services |   |   |   |
| Net sales | 96169 | 85200 | 78129 |
| Cost of sales | 25119 | 24855 | 22075 |






<!-- === R4.htm === -->



| CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions | 12 Months Ended |   |   |
| --- | --- | --- | --- |
|   | Sep. 28, 2024 | Sep. 30, 2023 | Sep. 24, 2022 |
| Statement of Comprehensive Income [Abstract] |   |   |   |
| Net income | 93736 | 96995 | 99803 |
| Other comprehensive income/(loss): |   |   |   |
| Change in foreign currency translation, net of tax | 395 | -765 | -1511 |
| Change in unrealized gains/losses on derivative instruments, net of tax: |   |   |   |
| Change in fair value of derivative instruments | -832 | 323 | 3212 |
| Adjustment for net (gains)/losses realized and included in net income | -1337 | -1717 | -1074 |
| Total change in unrealized gains/losses on derivative instruments | -2169 | -1394 | 2138 |
| Change in unrealized gains/losses on marketable debt securities, net of tax: |   |   |   |
| Change in fair value of marketable debt securities | 5850 | 1563 | -12104 |
| Adjustment for net (gains)/losses realized and included in net income | 204 | 253 | 205 |
| Total change in unrealized gains/losses on marketable debt securities | 6054 | 1816 | -11899 |
| Total other comprehensive income/(loss) | 4280 | -343 | -11272 |
| Total comprehensive income | 98016 | 96652 | 88531 |






<!-- === R5.htm === -->



| CONSOLIDATED BALANCE SHEETS - USD ($) shares in Thousands, $ in Millions | Sep. 28, 2024 | Sep. 30, 2023 |
| --- | --- | --- |
| Current assets: |   |   |
| Cash and cash equivalents | 29943 | 29965 |
| Marketable securities | 35228 | 31590 |
| Accounts receivable, net | 33410 | 29508 |
| Vendor non-trade receivables | 32833 | 31477 |
| Inventories | 7286 | 6331 |
| Other current assets | 14287 | 14695 |
| Total current assets | 152987 | 143566 |
| Non-current assets: |   |   |
| Marketable securities | 91479 | 100544 |
| Property, plant and equipment, net | 45680 | 43715 |
| Other non-current assets | 74834 | 64758 |
| Total non-current assets | 211993 | 209017 |
| Total assets | 364980 | 352583 |
| Current liabilities: |   |   |
| Accounts payable | 68960 | 62611 |
| Other current liabilities | 78304 | 58829 |
| Deferred revenue | 8249 | 8061 |
| Commercial paper | 9967 | 5985 |
| Term debt | 10912 | 9822 |
| Total current liabilities | 176392 | 145308 |
| Non-current liabilities: |   |   |
| Term debt | 85750 | 95281 |
| Other non-current liabilities | 45888 | 49848 |
| Total non-current liabilities | 131638 | 145129 |
| Total liabilities | 308030 | 290437 |
| Commitments and contingencies |   |   |
| Common stock, shares outstanding (in shares) | 15116786 | 15550061 |
| Common stock, shares issued (in shares) | 15116786 | 15550061 |
| Shareholders’ equity: |   |   |
| Common stock and additional paid-in capital, $0.00001 par value: 50,400,000 shares authorized; 15,116,786 and 15,550,061 shares issued and outstanding, respectively | 83276 | 73812 |
| Accumulated deficit | -19154 | -214 |
| Accumulated other comprehensive loss | -7172 | -11452 |
| Total shareholders’ equity | 56950 | 62146 |
| Total liabilities and shareholders’ equity | 364980 | 352583 |






<!-- === R6.htm === -->



| CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | Sep. 28, 2024 | Sep. 30, 2023 |
| --- | --- | --- |
| Statement of Financial Position [Abstract] |   |   |
| Common stock, par value (in dollars per share) | 0.00001 | 0.00001 |
| Common stock, shares authorized (in shares) | 50400000000 | 50400000000 |
| Common stock, shares issued (in shares) | 15116786000 | 15550061000 |
| Common stock, shares outstanding (in shares) | 15116786000 | 15550061000 |






<!-- === R7.htm === -->



| CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Millions | Total | Common stock and additional paid-in capital | Retained earnings/(Accumulated deficit) | Accumulated other comprehensive income/(loss) |
| --- | --- | --- | --- | --- |
| Beginning balances at Sep. 25, 2021 | 63090 | 57365 | 5562 | 163 |
| Increase (Decrease) in Stockholders' Equity [Roll Forward] |   |   |   |   |
| Common stock issued |   | 1175 |   |   |
| Common stock withheld related to net share settlement of equity awards |   | -2971 | -3454 |   |
| Share-based compensation |   | 9280 |   |   |
| Net income | 99803 |   | 99803 |   |
| Dividends and dividend equivalents declared |   |   | -14793 |   |
| Common stock repurchased |   |   | -90186 |   |
| Other comprehensive income/(loss) | -11272 |   |   | -11272 |
| Ending balances at Sep. 24, 2022 | 50672 | 64849 | -3068 | -11109 |
| Increase (Decrease) in Stockholders' Equity [Roll Forward] |   |   |   |   |
| Dividends and dividend equivalents declared per share or RSU (in dollars per share or RSU) | 0.90 |   |   |   |
| Common stock issued |   | 1346 |   |   |
| Common stock withheld related to net share settlement of equity awards |   | -3521 | -2099 |   |
| Share-based compensation |   | 11138 |   |   |
| Net income | 96995 |   | 96995 |   |
| Dividends and dividend equivalents declared |   |   | -14996 |   |
| Common stock repurchased |   |   | -77046 |   |
| Other comprehensive income/(loss) | -343 |   |   | -343 |
| Ending balances at Sep. 30, 2023 | 62146 | 73812 | -214 | -11452 |
| Increase (Decrease) in Stockholders' Equity [Roll Forward] |   |   |   |   |
| Dividends and dividend equivalents declared per share or RSU (in dollars per share or RSU) | 0.94 |   |   |   |
| Common stock issued |   | 1423 |   |   |
| Common stock withheld related to net share settlement of equity awards |   | -3993 | -1612 |   |
| Share-based compensation |   | 12034 |   |   |
| Net income | 93736 |   | 93736 |   |
| Dividends and dividend equivalents declared |   |   | -15218 |   |
| Common stock repurchased | -95000 |   | -95846 |   |
| Other comprehensive income/(loss) | 4280 |   |   | 4280 |
| Ending balances at Sep. 28, 2024 | 56950 | 83276 | $ (19,154) | $ (7,172) |
| Increase (Decrease) in Stockholders' Equity [Roll Forward] |   |   |   |   |
| Dividends and dividend equivalents declared per share or RSU (in dollars per share or RSU) | 0.98 |   |   |   |






<!-- === R8.htm === -->



| CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions | 12 Months Ended |   |   |
| --- | --- | --- | --- |
|   | Sep. 28, 2024 | Sep. 30, 2023 | Sep. 24, 2022 |
| Statement of Cash Flows [Abstract] |   |   |   |
| Cash, cash equivalents, and restricted cash and cash equivalents, beginning balances | 30737 | 24977 | 35929 |
| Operating activities: |   |   |   |
| Net income | 93736 | 96995 | 99803 |
| Adjustments to reconcile net income to cash generated by operating activities: |   |   |   |
| Depreciation and amortization | 11445 | 11519 | 11104 |
| Share-based compensation expense | 11688 | 10833 | 9038 |
| Other | -2266 | -2227 | 1006 |
| Changes in operating assets and liabilities: |   |   |   |
| Accounts receivable, net | -3788 | -1688 | -1823 |
| Vendor non-trade receivables | -1356 | 1271 | -7520 |
| Inventories | -1046 | -1618 | 1484 |
| Other current and non-current assets | -11731 | -5684 | -6499 |
| Accounts payable | 6020 | -1889 | 9448 |
| Other current and non-current liabilities | 15552 | 3031 | 6110 |
| Cash generated by operating activities | 118254 | 110543 | 122151 |
| Investing activities: |   |   |   |
| Purchases of marketable securities | -48656 | -29513 | -76923 |
| Proceeds from maturities of marketable securities | 51211 | 39686 | 29917 |
| Proceeds from sales of marketable securities | 11135 | 5828 | 37446 |
| Payments for acquisition of property, plant and equipment | -9447 | -10959 | -10708 |
| Other | -1308 | -1337 | -2086 |
| Cash generated by/(used in) investing activities | 2935 | 3705 | -22354 |
| Financing activities: |   |   |   |
| Payments for taxes related to net share settlement of equity awards | -5441 | -5431 | -6223 |
| Payments for dividends and dividend equivalents | -15234 | -15025 | -14841 |
| Repurchases of common stock | -94949 | -77550 | -89402 |
| Proceeds from issuance of term debt, net | 0 | 5228 | 5465 |
| Repayments of term debt | -9958 | -11151 | -9543 |
| Proceeds from/(Repayments of) commercial paper, net | 3960 | -3978 | 3955 |
| Other | -361 | -581 | -160 |
| Cash used in financing activities | -121983 | -108488 | -110749 |
| Increase/(Decrease) in cash, cash equivalents, and restricted cash and cash equivalents | -794 | 5760 | -10952 |
| Cash, cash equivalents, and restricted cash and cash equivalents, ending balances | 29943 | 30737 | 24977 |
| Supplemental cash flow disclosure: |   |   |   |
| Cash paid for income taxes, net | 26102 | 18679 | 19573 |





